Jonathan Klein concentrates his practice in the areas of mergers and acquisitions, private equity, corporate finance, securities matters and restructuring for both domestic and international clients. Mr. Klein is chair of the Mergers and Acquisitions group and heads the New York Corporate and Finance department.

Mr. Klein has represented public and private companies in negotiated domestic and cross border acquisitions and dispositions (including mergers, stock transactions, asset deals and divestitures), as well as bidders in contested transactions. Mr. Klein's private equity experience includes domestic and international leveraged transactions for both financial and strategic parties. His corporate finance experience includes public and private offerings of equity and debt securities.

Mr. Klein's general corporate practice includes advising public companies on SEC compliance and reporting issues, internal investigations, joint ventures, licensing and distribution agreements and providing general corporate advice and counsel to public and private companies, partnerships and individuals. He regularly counsels senior management, corporate boards and controlling stockholders with respect to acquisitions, dispositions, buyouts and general corporate and securities matters.

Mr. Klein has represented US and foreign clients in connection with cross-border acquisitions, divestitures, joint ventures, private financings, loan restructurings and workouts and general corporate matters.

REPRESENTATIVE MATTERS

Mr. Klein has represented:

• Pfizer Inc. in its sale of its Nutrition business to Nestle
• Pfizer Inc in connection with its acquisition of Alacer Corp., maker of the Emergen-C line fo products
• Investindustrial and its portfolio company, Polynt SpA in connection with their acquisition of the North American coatings and composite resin business of Momentive Corporation (formerly Hexion)
• Pfizer Inc. in connection with the divesiture of material portions of Pfizer's and Wyeth's animal health business to Boerhinger Ingelheim (which divestitures were mandated by the FTC as a condition to its approval of the Pfizer/Wyeth merger)
• Invitrogen Corporation (now known as Life Technologies) in connection with its US$6.7 billion merger with Applera Corporation (Applied Biosystems, Inc.)
• China Hydroelectric Corporation in connection with its US$96 million IPO and related NYSE listing; $400 million in private financing transactions; and related acquisitions of hydroelectric facilities in the Peoples Republic of China
• CK Life Sciences in acquisition of Vitaquest International
• NEC Corporation in acquisition of NetCracker Technology Corporation
• The Rank Group plc. in connection with its sale of The Hard Rock International to the Seminole Indian Tribe of Florida
• Atkins Nutritionals in connection with its sale to North Castle Partners
• Carat Duchatelet in connection with its acquisition of Centigon Holdings from BAE Systems
• Emirates Investment and Development Corp. in connection with its acquisition of Sino Swearingen Aircraft Corp (now knows as Emivest Aerospace)
• Arc International in connection with its sale of Mikasa Inc. to Lifetime Brands
• Adelphia Communications Corp. in connection with its post-bankruptcy liquidation matters
• NTL Europe, Inc. in the restructuring and sale of Cablecom Communications Corp., the largest Swiss cable company
• NTL Europe, Inc. in connection with its going-private transaction
• Mansueto Ventures in connection with the acquisition of Inc. and Fast Company magazines